Showing 1 - 8 of 8
The cost-effectiveness of hormone replacement therapy (HRT) based on a societal perspective is reassessed based on new medical evidence found in the Women's Health Initiative (WHI). Within a model framework using an individual state transition model the cost-effectiveness of 50-60 year old women...
Persistent link: https://www.econbiz.de/10002482555
This paper deals with the question how to model health effects after the cessation of a randomised controlled trial (RCT). Using clinical trial data on severe congestive heart failure patients we illustrate how survival beyond the cessation of a RCT can be predicted based on parametric survival...
Persistent link: https://www.econbiz.de/10001600068
Persistent link: https://www.econbiz.de/10001607830
Background: The Fracture Intervention Trial (FIT) showed that the bisphosphonate alendronate reduces the risk of fractures in women with low bone mass in the United States. Objective: To estimate the cost-effectiveness (cost per life-year gained and cost per quality-adjusted life-year, QALY,...
Persistent link: https://www.econbiz.de/10001673640
Persistent link: https://www.econbiz.de/10000956035
The value of preventing a fatality or (saving) a statistical life is an important question in health economics as well as environmental economics. This paper reviews and adds new insights to several of the issues discussed in the literature. For example, how do we define the value of a...
Persistent link: https://www.econbiz.de/10001645580
Persistent link: https://www.econbiz.de/10000924451
Persistent link: https://www.econbiz.de/10000910746